Home › Companies › Inhibikase Therapeutics, Inc. › 2025-2026
At Inhibikase Therapeutics, Inc.'s shareholder meeting held June 26, 2026, in the 2025-2026 proxy season, 94 asset managers reported how they voted in their SEC Form N-PX filings, covering 839 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Inhibikase Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 29, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Inhibikase Therapeutics, Inc.’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 26, 2026: 6 items on Inhibikase Therapeutics, Inc.’s Form 8-K, filed June 29, 2026: 2 elected · 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Inhibikase Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Inhibikase Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Arvind Kush | 70,338,595 | -- | -- | 12,770,121 | 23,911,956 | 85% | Elected | — |
| Elect Director: Dennis Berman | 64,127,395 | -- | -- | 18,981,321 | 23,911,956 | 77% | Elected | — |
| 2. To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 106,910,712 | 96,428 | 13,532 | -- | 0 | 99.9% | Not verified | — |
| 3. To approve an amendment to the Company's certificate of incorporation to limit the liability of certain officers of the Company as permitted by Delaware law | 82,321,246 | 779,416 | 8,054 | -- | 23,911,956 | 99.0% | Not verified | — |
| 4. To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the authorized number of shares of common stock reserved for issuance by 3,000,000 shares | 60,795,802 | 22,135,512 | 177,402 | -- | 23,911,956 | 73% | Not verified | — |
| 5. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 61,237,304 | 21,648,671 | 222,741 | -- | 23,911,956 | 74% | Not verified | — |
Source: Inhibikase Therapeutics, Inc., Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.
Each item below shows how the 94 asset managers that disclosed a Inhibikase Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Inhibikase Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors, to the Board of Directors, each to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Arvind Kush
Inhibikase Therapeutics, Inc.’s own tally for this item (“Elect Director: Arvind Kush”): 70,338,595 for, 12,770,121 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Arvind Kush and Dennis Berman were duly elected to the Board of Directors as Class III directors, each to serve until the Company's 2029 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation or removal:”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 5,307,251 for, 56,069 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,397,324 | 0 | 17 | 2,540 | For |
| BlackRock | 2,306,124 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 174,150 | 0 | 0 | 0 | For |
| Fidelity | 132,529 | 0 | 0 | 5,670 | For |
| Lincoln Financial | 48,000 | 0 | 0 | 0 | For |
| Global X | 46,498 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,523 | 0 | 0 | 0 | For |
| Pacific Life | 37,543 | 0 | 0 | 0 | For |
| JPMorgan | 35,546 | 0 | 0 | 0 | For |
| Northern Trust | 20,374 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 17,842 | Withhold |
| Equitable | 17,805 | 0 | 0 | 0 | For |
| Charles Schwab | 11,779 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 10,099 | Withhold |
| SEI | 7,800 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 6,961 | Withhold |
| Voya | 6,617 | 0 | 0 | 0 | For |
| TIAA | 6,257 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 6,174 | Withhold |
| Venerable Variable Insurance Trust | 5,009 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 3,994 | Withhold |
| State Street | 3,869 | 0 | 0 | 0 | For |
| Brighthouse | 3,002 | 0 | 0 | 1 | For |
| PENN SERIES FUNDS INC | 2,300 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,165 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors, to the Board of Directors, each to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Dennis Berman
Inhibikase Therapeutics, Inc.’s own tally for this item (“Elect Director: Dennis Berman”): 64,127,395 for, 18,981,321 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Arvind Kush and Dennis Berman were duly elected to the Board of Directors as Class III directors, each to serve until the Company's 2029 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation or removal:”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 2,510,968 for, 2,852,343 withheld, 25 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,394,682 | 0 | 25 | 5,173 | For |
| BlackRock | 0 | 0 | 0 | 2,306,124 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 174,150 | Withhold |
| Fidelity | 0 | 0 | 0 | 138,199 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 48,000 | Withhold |
| Global X | 46,498 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 0 | 42,523 | Withhold |
| Pacific Life | 0 | 0 | 0 | 37,543 | Withhold |
| JPMorgan | 35,546 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 20,374 | Withhold |
| John Hancock | 0 | 0 | 0 | 17,842 | Withhold |
| Equitable | 0 | 0 | 0 | 17,805 | Withhold |
| Charles Schwab | 11,779 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 10,099 | Withhold |
| SEI | 7,800 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 6,961 | Withhold |
| Voya | 6,617 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 6,257 | Withhold |
| Calvert | 0 | 0 | 0 | 6,174 | Withhold |
| Venerable Variable Insurance Trust | 5,009 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 3,994 | Withhold |
| State Street | 0 | 0 | 0 | 3,869 | Withhold |
| Brighthouse | 3,002 | 0 | 0 | 1 | For |
| PENN SERIES FUNDS INC | 0 | 0 | 0 | 2,300 | Withhold |
| Brinker Capital Destinations Trust | 0 | 0 | 0 | 2,165 | Withhold |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to the Company's certificate of incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.
Inhibikase Therapeutics, Inc.’s own tally for this item (“3. To approve an amendment to the Company's certificate of incorporation to limit the liability of certain officers of the Company as permitted by Delaware law”): 82,321,246 for, 779,416 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 5,302,941 for, 100,396 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,397,340 | 2,541 | 0 | 0 | For |
| BlackRock | 2,306,124 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 174,150 | 0 | 0 | 0 | For |
| Fidelity | 138,199 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,000 | 0 | 0 | 0 | For |
| Global X | 0 | 46,498 | 0 | 0 | Against |
| Bridge Builder Trust | 42,523 | 0 | 0 | 0 | For |
| 360 Funds | 40,000 | 0 | 0 | 0 | For |
| Pacific Life | 37,543 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 35,546 | 0 | 0 | Against |
| Northern Trust | 20,374 | 0 | 0 | 0 | For |
| John Hancock | 17,842 | 0 | 0 | 0 | For |
| Equitable | 17,805 | 0 | 0 | 0 | For |
| Charles Schwab | 11,779 | 0 | 0 | 0 | For |
| ProShares | 10,099 | 0 | 0 | 0 | For |
| SEI | 0 | 7,800 | 0 | 0 | Against |
| AIG/SunAmerica | 6,961 | 0 | 0 | 0 | For |
| Voya | 6,617 | 0 | 0 | 0 | For |
| TIAA | 6,257 | 0 | 0 | 0 | For |
| Calvert | 6,174 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 0 | 5,009 | 0 | 0 | Against |
| Principal | 3,994 | 0 | 0 | 0 | For |
| State Street | 3,869 | 0 | 0 | 0 | For |
| Brighthouse | 1 | 3,002 | 0 | 0 | Against |
| PENN SERIES FUNDS INC | 2,300 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the authorized number of shares of common stock reserved for issuance by 3,000,000 shares.
Inhibikase Therapeutics, Inc.’s own tally for this item (“4. To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the authorized number of shares of common stock reserved for issuance by 3,000,000 shares”): 60,795,802 for, 22,135,512 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,940 | 2,395,941 | 0 | 0 | Against |
| BlackRock | 0 | 2,306,124 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 174,150 | 0 | 0 | Against |
| Fidelity | 0 | 138,199 | 0 | 0 | Against |
| Lincoln Financial | 0 | 48,000 | 0 | 0 | Against |
| Global X | 0 | 46,498 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 42,523 | 0 | 0 | Against |
| 360 Funds | 40,000 | 0 | 0 | 0 | For |
| Pacific Life | 0 | 37,543 | 0 | 0 | Against |
| JPMorgan | 0 | 35,546 | 0 | 0 | Against |
| Northern Trust | 0 | 20,374 | 0 | 0 | Against |
| John Hancock | 0 | 17,842 | 0 | 0 | Against |
| Equitable | 0 | 17,805 | 0 | 0 | Against |
| Charles Schwab | 0 | 11,779 | 0 | 0 | Against |
| ProShares | 0 | 10,099 | 0 | 0 | Against |
| SEI | 0 | 7,800 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 6,961 | 0 | 0 | Against |
| Voya | 0 | 6,617 | 0 | 0 | Against |
| TIAA | 0 | 6,257 | 0 | 0 | Against |
| Calvert | 0 | 6,174 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 0 | 5,009 | 0 | 0 | Against |
| Principal | 0 | 3,994 | 0 | 0 | Against |
| State Street | 0 | 3,869 | 0 | 0 | Against |
| Brighthouse | 0 | 3,003 | 0 | 0 | Against |
| PENN SERIES FUNDS INC | 0 | 2,300 | 0 | 0 | Against |
Fund voting reports, all 34 managers: 43,940 for, 5,359,397 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Saturn V Capital Management LP | 3,863,445 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 795,104 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 4,658,549 for.
Combines 4 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Inhibikase Therapeutics, Inc.’s own tally for this item (“5. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 61,237,304 for, 21,648,671 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,940 | 2,395,941 | 0 | 0 | Against |
| BlackRock | 0 | 2,306,124 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 174,150 | 0 | 0 | Against |
| Fidelity | 0 | 138,199 | 0 | 0 | Against |
| Lincoln Financial | 0 | 48,000 | 0 | 0 | Against |
| Global X | 0 | 46,498 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 42,523 | 0 | 0 | Against |
| Pacific Life | 0 | 37,543 | 0 | 0 | Against |
| JPMorgan | 35,546 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 20,374 | 0 | 0 | Against |
| John Hancock | 0 | 17,842 | 0 | 0 | Against |
| Equitable | 0 | 17,805 | 0 | 0 | Against |
| Charles Schwab | 0 | 11,779 | 0 | 0 | Against |
| ProShares | 0 | 10,099 | 0 | 0 | Against |
| SEI | 0 | 7,800 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 6,961 | 0 | 0 | Against |
| Voya | 6,617 | 0 | 0 | 0 | For |
| TIAA | 0 | 6,257 | 0 | 0 | Against |
| Calvert | 0 | 6,174 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 0 | 5,009 | 0 | 0 | Against |
| Principal | 0 | 3,994 | 0 | 0 | Against |
| State Street | 0 | 3,869 | 0 | 0 | Against |
| Brighthouse | 3,002 | 1 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 0 | 2,300 | 0 | 0 | Against |
| Brinker Capital Destinations Trust | 0 | 2,165 | 0 | 0 | Against |
Fund voting reports, all 33 managers: 49,140 for, 5,314,197 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 9,383,249 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 8,625,000 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 8,079,415 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 5,850,000 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 0 | 5,696,203 | 0 | 0 | Against |
| Commodore Capital LP | 5,397,488 | 0 | 0 | 0 | For |
| Blackstone Inc. | 0 | 4,184,563 | 0 | 0 | Against |
| Saturn V Capital Management LP | 3,863,445 | 0 | 0 | 0 | For |
| Sands Capital Alternatives, LLC | 2,068,965 | 0 | 0 | 0 | For |
| BlackRock | 5,221 | 1,745,887 | 0 | 0 | Against |
| SummitTX Capital, L.P. | 933,039 | 0 | 0 | 0 | For |
| State Street | 924 | 898,136 | 0 | 0 | Against |
| Stonepine Capital Management, LLC | 800,857 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 795,104 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 519,072 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 462,488 | 0 | 0 | Against |
| Citadel | 430,360 | 0 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 355,610 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 288,479 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 238,450 | 0 | 0 | 0 | For |
| Edward D. Jones & Co., L.P. | 0 | 92,200 | 0 | 0 | Against |
| ALGERT GLOBAL LLC | 0 | 0 | 76,223 | 0 | Abstain |
| BLAIR WILLIAM & CO/IL | 0 | 65,976 | 0 | 0 | Against |
| JPMorgan | 56,122 | 0 | 0 | 0 | For |
| Nuveen | 0 | 54,219 | 0 | 0 | Against |
Institutional-manager reports, all 73 managers: 46,917,386 for, 14,422,812 against, 76,223 abstained, 18,616 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: TO VOTE, ON A NON-BINDING, ADVISORY BASIS, ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Calvert | 0 | 0 | 0 | 0 | -- |
| Venerable Variable Insurance Trust | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 3,003 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Brinker Capital Destinations Trust | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 33 managers: 3,003 for, 5,355,052 1 year, 5,281 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 0 | 0 | 0 | 0 | -- |
| Fairmount Funds Management LLC | 0 | 0 | 0 | 0 | -- |
| Trails Edge Capital Partners, LP | 8,079,415 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| ADAR1 Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Commodore Capital LP | 0 | 0 | 0 | 0 | -- |
| Blackstone Inc. | 0 | 0 | 0 | 0 | -- |
| Sands Capital Alternatives, LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| SummitTX Capital, L.P. | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Integral Health Asset Management, LLC | 795,104 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Ally Bridge Group (NY) LLC | 355,610 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Edward D. Jones & Co., L.P. | 0 | 0 | 0 | 0 | -- |
| BLAIR WILLIAM & CO/IL | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| Rhumbline | 0 | 18,616 | 0 | 0 | Against |
Institutional-manager reports, all 69 managers: 9,230,129 for, 18,616 against, 47,445,446 1 year. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Inhibikase Therapeutics, Inc.’s own tally for this item (“2. To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 106,910,712 for, 96,428 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 5,363,337 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,399,881 | 0 | 0 | 0 | For |
| BlackRock | 2,306,124 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 174,150 | 0 | 0 | 0 | For |
| Fidelity | 138,199 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,000 | 0 | 0 | 0 | For |
| Global X | 46,498 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,523 | 0 | 0 | 0 | For |
| Pacific Life | 37,543 | 0 | 0 | 0 | For |
| JPMorgan | 35,546 | 0 | 0 | 0 | For |
| Northern Trust | 20,374 | 0 | 0 | 0 | For |
| John Hancock | 17,842 | 0 | 0 | 0 | For |
| Equitable | 17,805 | 0 | 0 | 0 | For |
| Charles Schwab | 11,779 | 0 | 0 | 0 | For |
| ProShares | 10,099 | 0 | 0 | 0 | For |
| SEI | 7,800 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 6,961 | 0 | 0 | 0 | For |
| Voya | 6,617 | 0 | 0 | 0 | For |
| TIAA | 6,257 | 0 | 0 | 0 | For |
| Calvert | 6,174 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 5,009 | 0 | 0 | 0 | For |
| Principal | 3,994 | 0 | 0 | 0 | For |
| State Street | 3,869 | 0 | 0 | 0 | For |
| Brighthouse | 3,003 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 2,300 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,165 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 132,032,636 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.82% |
| 2 | BlackRock | 1.75% |
| 3 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 4 | Fidelity | 0.10% |
| 5 | Lincoln Financial | 0.04% |
| 6 | Global X | 0.04% |
| 7 | Bridge Builder Trust | 0.03% |
| 8 | 360 Funds | 0.03% |
| 9 | Pacific Life | 0.03% |
| 10 | JPMorgan | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Soleus Capital Management, L.P. | 7.11% |
| 2 | Fairmount Funds Management LLC | 6.53% |
| 3 | Trails Edge Capital Partners, LP | 6.12% |
| 4 | Siren, L.L.C. | 4.43% |
| 5 | ADAR1 Capital Management, LLC | 4.31% |
| 6 | Commodore Capital LP | 4.09% |
| 7 | Blackstone Inc. | 3.17% |
| 8 | Saturn V Capital Management LP | 2.93% |
| 9 | Sands Capital Alternatives, LLC | 1.57% |
| 10 | BlackRock | 1.33% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Soleus Capital | — | DEF14A |
| Fairmount Healthcare Fund II L.P. | — | DEF14A |
| RA Capital Management, L.P. | — | 13G |
| SP IKT Holdings LLC | — | DEF14A |
| Commodore Capital LP | — | 13G |
| ADAR1 Capital Management, LLC | — | 13G |
| Sands Capital Life Sciences Pulse Fund II, L.P. | — | 13G |
| Fairmount Funds Management LLC | — | 13G |
| Perceptive Advisors LLC | — | 13G |
| Trails Edge Capital Partners, LP | — | 13G |
Percentages above are of 132,032,636 shares outstanding, as reported by Inhibikase Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Inhibikase Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Inhibikase Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Inhibikase Therapeutics (IKT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/inhibikase-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.